Bagsværd, Denmark, 21
“There is a significant unmet medical need within obesity treatment today. With oral semaglutide we aim to introduce a convenient and effective treatment option for people with obesity and healthcare providers enabling broader use of anti-obesity medication,” said
About obesity
Obesity is a chronic disease that requires long-term management. It is associated with many serious health complications and decreased life expectancy. Obesity-related complications are numerous and include type 2 diabetes, cardiovascular disease, obstructive sleep apnoea, non-alcoholic fatty liver disease and certain types of cancer. The current COVID-19 pandemic has shown that obesity also increases the risk of severe illness and hospitalisation due to COVID-19.
The global increase in the prevalence of obesity is a public health issue that has severe cost implications to healthcare systems. Approximately 650 million adults are estimated to live with obesity worldwide.
About semaglutide 2.4 mg for weight management and STEP
Once-weekly sc semaglutide 2.4 mg is currently under regulatory review in the US and the EU as a treatment for adults with obesity. Semaglutide is an analogue of the human glucagon-like peptide-1 (GLP-1) hormone. It induces weight loss by reducing hunger, increasing feeling of fullness and thereby helping people eat less and reduce their calorie intake.
The submissions for regulatory review are based on the results from the STEP (Semaglutide Treatment Effect in People with obesity) phase 3 clinical development programme. The global clinical phase 3a programme consisted of four trials and enrolled approximately 4,500 adults with overweight or obesity.
About oral semaglutide
Oral semaglutide (7 mg and 14 mg) is approved as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes in the US, EU and
About
Further information
Media: | ||
+45 3079 3883 | mkd@novonordisk.com | |
+1 609 664 7308 | mzyb@novonordisk.com | |
Investors: | ||
Daniel Muusmann Bohsen | +45 3075 2175 | dabo@novonordisk.com |
+45 3079 0301 | jvls@novonordisk.com | |
Ann Søndermølle Rendbæk | +45 3075 2253 | arnd@novonordisk.com |
+45 3079 4211 | mjhr@novonordisk.com | |
+1 609 235 2989 | krdb@novonordisk.com |
Company announcement No 25 / 2021
Attachment
- PR210421_Oral_obesity_initiation
© OMX, source